Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma

NCT01348503 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped Treatment was ineffective

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Lenalidomide
DRUG: Sorafenib

Sponsor

Indiana University

Collaborators

[object Object]